LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.

Back to top Dr. Balachandran is affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research. The phase 1 clinical trial was sponsored by Memorial Sloan Kettering Cancer Center. The ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. The ...

The US clinical trials market is extensively segmented by different phases of clinical research, service types, indications, and geographical landscapes. The segmentation is indicative of a ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

CERo Therapeutics (CERO) announces the execution of an agreement with contract research organization CellCarta to manage translational assays ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP ...